Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.54 |
| ▸ | HRH1 | P35367 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | PDE6D | O43924 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864784 | 0.90 | HTR3A (0.57) | HTR3ACYP2D6HRH1SMN1; SMN2NPSR1 | |
| SCHEMBL3866023 | 0.86 | DRD2 (0.61) | HTR3ADRD2TBXA2RCYP2D6HRH1 | |
| SCHEMBL7341277 | 0.86 | HTR3A (0.75) | HTR3ACYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL8879353 | 0.85 | HTR3A (0.57) | HTR3ACYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL8877905 | 0.84 | HTR3A (0.56) | HTR3ACYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL20715423 | 0.83 | CYP2D6 (0.66) | HTR3ACYP2D6HRH1NPSR1KCNH2 | |
| SCHEMBL20715427 | 0.82 | CYP2D6 (0.64) | HTR3ACYP2D6HRH1NPSR1KCNH2 | |
| SCHEMBL13186945 | 0.82 | CYP1A2 (0.77) | AGTR1AGTR2CYP2D6HRH1NPSR1 | |
| SCHEMBL7168715 | 0.81 | HTR3A (0.81) | HTR3ACYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL28989060 | 0.79 | AGTR1 (0.67) | AGTR1AGTR2PPARGDRD2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-7393859-B2 | Amide substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1187613-B9 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1187613-B1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20040229897-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-18 | — | — | US | disclosed |
| US-6756382-B2 | SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-29 | — | — | US | disclosed |
| US-20030144283-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-31 | — | — | US | disclosed |
| US-6451810-B1 | AID IN CYTOKINE BIOSYNTHESIS | 3M INNOVATIVE PROPERTIES COMPANY | 2002-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229897-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | HTR3A 4679/4885AGTR1 526/4885AGTR2 773/4885 |
| US-20090023722-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IRF3, EIF2AK2 | HTR3A 4679/4885AGTR1 526/4885AGTR2 773/4885 |
| US-20030144283-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | HTR3A 4679/4885AGTR1 526/4885AGTR2 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.